<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="letter"><?properties open_access?><!-- Original-type: sc--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16721369</article-id><article-id pub-id-type="pmc">2361302</article-id><article-id pub-id-type="pii">6603174</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6603174</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eickhoff</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hartmann</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Eickhoff</surname><given-names>J C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000f6;hler</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Galle</surname><given-names>P R</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Riemann</surname><given-names>J F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jakobs</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Medical Department C, Klinikum Ludwigshafen gGmbH, Bremserstr.79</institution> Ludwigshafen D-67063, <country>Germany</country></aff><aff id="aff2"><label>2</label><institution>Department of Biostatistics and Medical Informatics, University of Wisconsin</institution> Madison, WI, <country>USA</country></aff><aff id="aff3"><label>3</label><institution>I. Medical Clinic, Johannes Gutenberg University Mainz</institution> Mainz, <country>Germany</country></aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:eickhofa@klilu.de">eickhofa@klilu.de</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>05</month><year>2006</year></pub-date><pub-date pub-type="collection"><day>30</day><month>05</month><year>2006</year></pub-date><pub-date pub-type="ppub"><day>05</day><month>06</month><year>2006</year></pub-date><volume>94</volume><issue>11</issue><fpage>1572</fpage><lpage>1574</lpage><history><date date-type="received"><day>10</day><month>02</month><year>2006</year></date><date date-type="rev-recd"><day>18</day><month>04</month><year>2006</year></date><date date-type="accepted"><day>19</day><month>04</month><year>2006</year></date></history><copyright-statement>Copyright 2006, Cancer Research UK</copyright-statement><copyright-year>2006</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and EPI 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.</p></abstract><kwd-group><kwd>pancreatic cancer</kwd><kwd>chemotherapy</kwd><kwd>gemcitabine</kwd><kwd>epirubicin</kwd></kwd-group></article-meta></front><body><p>Pancreatic cancer is one of the most aggressive human cancers with an extremely poor prognosis. In 1998, gemcitabine (GEM) was approved for use in the palliative treatment approach (<xref ref-type="other" rid="bib3">Burris <italic>et al</italic>, 1997</xref>). However, even with GEM, monotherapy has obvious limitations in advanced pancreatic cancer and various combinations with other agents have been investigated in phase III trials as well (<xref ref-type="other" rid="bib2">Burris, 2005</xref>).</p><p><italic>In vitro</italic> studies in solid tumour cell lines have demonstrated that pretreatment of cancer cells with the anthracycline epirubicin (EPI), followed by administration of GEM, inhibits proliferation and increases the rate of DNA fragmentation (<xref ref-type="other" rid="bib1">Angelucci <italic>et al</italic>, 1997</xref>). The aim of this study was to find the maximum-tolerated dose (MTD) of EPI in combination with GEM in pancreatic carcinoma. We also sought to evaluate the antitumour activity and the clinical benefit of this combination.</p><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Patient eligibility</title><p>Patients with unresectable pancreatic carcinoma with or without distant metastases were eligible for the trial. Eligibility criteria included age 18&#x02013;75 years, Karnofsky's performance status (KPS) &#x02a7e;60 and a left ventricular ejection fraction measured by multiple electrocardiogram-gated radionuclide study (MUGA-scan) higher than 50&#x00025;. Baseline laboratory requirements were defined as described elsewhere (<xref ref-type="other" rid="bib4">Hess <italic>et al</italic>, 2003</xref>). The study was carried out in accordance with the Declaration of Helsinki and approved by the local ethics committees; written informed consent was obtained from all patients.</p></sec><sec><title>Treatment</title><p>Gemcitabine (Gemzar&#x000ae;, Eli Lilly, Indianapolis, IN, USA) was administered as a 30-min i.v. infusion on days 1 and 8; EPI (Pharmacia, Erlangen, Germany) as an i.v. bolus injection over a period of 5&#x02009;min prior to GEM on day 8 of each 21-day cycle. In phase I the dose escalation to a maximum of six levels consisted of: Step 1: GEM 800&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, EPI 35&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> until Step 6: GEM 1000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, EPI 90&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>.</p></sec><sec><title>Toxicity score</title><p>Dose-limiting toxicity was defined, using the World Health Organization (WHO) criteria (<xref ref-type="other" rid="bib5">Miller <italic>et al</italic>, 1981</xref>). Complete blood cell counts were measured at days 1, 8 and 15 of each 21-day cycle.</p></sec><sec><title>Maximum-tolerated dose for phase I of gemcitabine and epirubicin</title><p>An open-label, phase I trial design with a standard dose escalation schedule was used to determine the MTD. The MTD was defined as the highest safely tolerated dose where at most one patient experienced dose-limiting toxicity (DLT) with the next higher dose having at least two patients who experienced DLT. A DLT was defined as described elsewhere (<xref ref-type="other" rid="bib9">Van Putten <italic>et al</italic>, 2000</xref>). Patients enrolled in cohorts of three. If no patients in a cohort experienced DLT in the first two cycles, escalation proceeded to the next higher dose level. If one of the first three patients experienced a DLT, three additional patients were added in that cohort. If no additional DLT's occurred, escalation continued. The MTD represents the dose recommended for the phase II trial.</p></sec><sec><title>Assessment of safety, efficacy and quality of life</title><p>Adverse events reported according to the standard World Health Organization (WHO) criteria were used for safety assessment (<xref ref-type="other" rid="bib5">Miller <italic>et al</italic>, 1981</xref>). Evaluation of tumour response was conducted according to standard WHO criteria. A responder was defined as any patient who had a complete or partial response, which was confirmed by a second evaluation with the same imaging technique at least 4 weeks later. Quality of life was measured with a standardised and validated questionnaire (Spitzer Quality of Life Index) and clinical benefit response was defined as in the study by <xref ref-type="other" rid="bib3">Burris <italic>et al</italic> (1997)</xref>.</p></sec><sec><title>Statistical analysis</title><p>Toxicity and efficacy were summarised by descriptive statistics. The tumour response was presented as percentage along with the 95&#x00025; confidence interval (CI). The significance level for each hypothesis test was 5&#x00025;. Median time to progression and overall survival time was calculated according to the Kaplan&#x02013;Meier product-limit method. Subgroups were compared using the log-rank test.</p></sec></sec><sec><title>RESULTS</title><p>Between May 2000 and 2003, a total of 40 symptomatic patients were enrolled in the study (<xref rid="tbl1" ref-type="table">Table 1</xref>). A total of 230 cycles of chemotherapy was administered with a median of six cycles per patient (range 2&#x02013;9).</p><p>Three patients were entered at each dose level 1, 2 and 3 in the phase I part. Six patients were assigned to dose level 4. At that dose level, two of six patients experienced DLT, which consisted of grade 3 neutropenia and anaemia in one patient and a febrile grade 4 neutro- and thrombocytopenia in a second patient. Therefore, dose level 3 (GEM 1000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and EPI 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>), was found to be the MTD for the phase II part. Overall, 28 patients were treated with GEM 1000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and EPI 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>.</p><sec><title>Toxicity</title><p>Haematological toxicity observed in the phase I part is shown in <xref rid="tbl2" ref-type="table">Table 2</xref>. Nonhaematological toxicity in these patients was mainly mild nausea/vomiting (grade 1/2). Two patients had grade 3 alopecia and mild gastrointestinal toxicity (diarrhoea) occurred in four patients. Five patients (33&#x00025;) experienced grades 1 and 2 mucositis, but this was manageable in all patients. A dose reduction was necessary in four patients, three of whom were treated at dose level 4. Renal, hepatic and neurologic toxicities were generally mild and no evidence of cardiac toxicity was recorded.</p><p>Overall, the 28 patients who were treated with the MTD of GEM 1000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and EPI 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> experienced only mild toxicity. Grade 3 haematologic toxicity occurred in one patient of phase I (anaemia) and one patient of phase II (neutropenia). In seven (25&#x00025;) patients dose reduction of both drugs to 75&#x00025; was necessary while one patient received dose reduction to 50&#x00025; due to leukopenia grade III in one cycle, and treatment delay for 1 week in another cycle.</p><p>One patient at this dose level experienced grade 3 nausea/vomiting. Chemically induced phlebitis due to EPI was noted only in one other patient. Hospitalisation was necessary for another patient due to pneumonia. No major hepatic, renal, cardiac and neurologic toxicities were seen as well (<xref rid="tbl3" ref-type="table">Table 3</xref>).</p></sec><sec><title>Tumour response and survival</title><p>The overall response rate was 23&#x00025; (95&#x00025; CI: 0.29&#x02013;0.62) based on nine of 40 patients with partial response. The median time to response was 3 (range 2.5&#x02013;3.7) months, and the median duration of response was 8.2 (range 4&#x02013;12) months. Stable disease (SD) occurred in 14 of 40 (35&#x00025;) patients. The remaining 17 (42.5&#x00025;) patients showed progressive disease. Median time to disease progression for all patients was 4.2 (range 2&#x02013;12) months.</p><p>The 6 months and 1-year survival rates were 55&#x00025; (22/40 patients) and 22.5&#x00025; (9/40 patients), respectively. The median overall survival time was 7.4 (range 2&#x02013;21.8) (95&#x00025; CI: 5.1&#x02013;9.9) months. For patients with tumour response (9/40 patients), the median survival was 12.6 (range 10.7&#x02013;21.8) months, and the probability of surviving beyond 1 year was 55&#x00025;. Patients with objective tumour response survived significantly longer than patients with no tumour response (<italic>P</italic>=0.01).</p></sec><sec><title>Clinical benefit response</title><p>Thirty-seven patients with tumour-related symptoms were considered evaluable for clinical benefit response. In 10/35 (29&#x00025;) patients suffering from pain at study entry, pain intensity and/or analgesic use was reduced at least by 50&#x00025; compared to baseline values, and 18 remained stable in this category. Improvement of KPS occurred in 13 (35&#x00025;) patients and performance status remained stable for 20 (54&#x00025;) patients during at least 4 weeks. Eight patients (21.6&#x00025;) had a weight gain of &#x02a7e;7&#x00025; from baseline during the study. Improvement of the quality of life during treatment measured and expressed with the Spitzer-activity-index was seen in 15 of 37 (40.5&#x00025;) patients. In the final assessment, a total of 18 patients were classified as clinical benefit responders, yielding a clinical response rate of 49&#x00025; (95&#x00025; CI: 0.29&#x02013;0.62). We observed a significant correlation between clinical benefit response and objective tumour response as well (<italic>P</italic>&#x0003c;0.001).</p></sec></sec><sec><title>DISCUSSION</title><p>Our experience with GEM and EPI clearly demonstrated that this combination is adequately tolerated with moderate toxicities that were qualitatively and quantitatively similar to those reported from other trials (<xref ref-type="other" rid="bib8">Scheithauer <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib6">Neri <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib7">Reni <italic>et al</italic>, 2005</xref>).</p><p>In line with the preclinical observation of synergy, the combination of GEM and EPI achieved a promising preliminary antitumour effect. In this trial, we achieved a 22.5&#x00025; overall remission rate in 40 evaluable patients and a median response duration of 8 months. With an additional 35&#x00025; of patients experiencing SD this combination achieved a favourable disease control in almost 60&#x00025; of patients. Three other GEM&#x0002b;EPI studies in pancreatic cancer have been published in manuscript form (<xref ref-type="other" rid="bib8">Scheithauer <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib6">Neri <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib7">Reni <italic>et al</italic>, 2005</xref>).</p><p>Concerning objective tumour response and disease control, the reported data are comparable (objective response 21&#x02013;51&#x00025;; disease control 65&#x02013;80&#x00025;) with our results. <xref ref-type="other" rid="bib6">Neri <italic>et al</italic> (2002)</xref> reported an overall response rate of 25&#x00025; and a SD in 41&#x00025; of their patients. Most patients (77&#x00025;) in that study were stage IV and two-thirds had a mean KPS between 70 and 80.</p><p>Comparable objective results were published by <xref ref-type="other" rid="bib8">Scheithauer <italic>et al</italic> (1999)</xref> with a combination of GEM 1000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x0002b;EPI 60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x0002b;granulocyte colony-stimulating factor. Recently, a phase III trial with GEM in combination with EPI, 5-FU and cisplatin <italic>vs</italic> GEM was published by <xref ref-type="other" rid="bib7">Reni <italic>et al</italic> (2005)</xref>. They found an overall response of 38.5&#x00025; and stabilisation of the disease in further 28.8&#x00025; with the combination therapy. Overall, these data from GEM&#x0002b;EPI trials supports the hope that some improvements in response rates and prognosis may be achievable.</p><p>In our study, we observed a clinical benefit response in 49&#x00025; of symptomatic patients. This compares favourably with the rate of clinical benefit response in the GEM&#x0002b;EPI studies by <xref ref-type="other" rid="bib8">Scheithauer <italic>et al</italic> (1999)</xref> (43&#x00025;) and <xref ref-type="other" rid="bib6">Neri <italic>et al</italic> (2002)</xref> (44&#x00025;). However, using the same validated definitions for clinical benefit response, there is almost a doubling of the rate of clinical benefit responders with the combination therapy in comparison with GEM alone (<xref ref-type="other" rid="bib3">Burris <italic>et al</italic>, 1997</xref>, <xref ref-type="other" rid="bib6">Neri <italic>et al</italic>, 2002</xref>).</p><p>In conclusion, this combination chemotherapy of GEM and EPI was well tolerated and feasible at the recommended dose level. The regimen is active with a high rate of clinical benefit responders. Whether addition of EPI to GEM is comparable to the combination of other drugs (cisplatin, irinotecan, 5-FU, and &#x02018;biologicals') and GEM should be further evaluated in randomised phase III trials.</p></sec></body><back><ack><p>This study was supported in part by Eli Lilly and Pharmacia Germany.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Angelucci</surname><given-names>A</given-names></name><name><surname>Alesse</surname><given-names>E</given-names></name><name><surname>Trotta</surname><given-names>I</given-names></name></person-group><article-title>Schedule-dependent and additive effects of doxorubicin and gemcitabine on tumor cell apoptosis</article-title><source>Tumori</source><year>1997</year><volume>83</volume><fpage>129</fpage><lpage>130</lpage><!--PubMed citation query: 'Tumori||83|129||bib1|'--></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burris</surname><given-names>HA</given-names><suffix>III</suffix></name></person-group><article-title>Recent updates on the role of chemotherapy in pancreatic cancer</article-title><source>Semin Oncol</source><year>2005</year><volume>32</volume><fpage>S1</fpage><lpage>S3</lpage><!--PubMed citation query: 'Semin Oncol||32|S1||bib2|'--></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burris</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Modiano</surname><given-names>MR</given-names></name><name><surname>Cripps</surname><given-names>MC</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name><name><surname>Storniolo</surname><given-names>AM</given-names></name><name><surname>Tarassoff</surname><given-names>P</given-names></name><name><surname>Nelson</surname><given-names>R</given-names></name><name><surname>Dorr</surname><given-names>FA</given-names></name><name><surname>Stephens</surname><given-names>CD</given-names></name><name><surname>Von Hoff</surname><given-names>DD</given-names></name></person-group><article-title>Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>2403</fpage><lpage>2413</lpage><!--PubMed citation query: 'J Clin Oncol||15|2403||bib3|'--><pub-id pub-id-type="pmid">9196156</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>V</given-names></name><name><surname>Salzberg</surname><given-names>M</given-names></name><name><surname>Borner</surname><given-names>M</given-names></name><name><surname>Morant</surname><given-names>R</given-names></name><name><surname>Roth</surname><given-names>AD</given-names></name><name><surname>Ludwig</surname><given-names>C</given-names></name><name><surname>Hermann</surname><given-names>R</given-names></name></person-group><article-title>Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>66</fpage><lpage>68</lpage><!--PubMed citation query: 'J Clin Oncol||21|66||bib4|'--><pub-id pub-id-type="pmid">12506172</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>AB</given-names></name><name><surname>Hoogstraten</surname><given-names>B</given-names></name><name><surname>Staquet</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>A</given-names></name></person-group><article-title>Reporting results of cancer treatment</article-title><source>Cancer</source><year>1981</year><volume>47</volume><fpage>207</fpage><lpage>214</lpage><!--PubMed citation query: 'Cancer||47|207||bib5|'--><pub-id pub-id-type="pmid">7459811</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neri</surname><given-names>B</given-names></name><name><surname>Cini</surname><given-names>G</given-names></name><name><surname>Doni</surname><given-names>L</given-names></name><name><surname>Fulignati</surname><given-names>C</given-names></name><name><surname>Turrini</surname><given-names>M</given-names></name><name><surname>Pantalone</surname><given-names>D</given-names></name><name><surname>Mini</surname><given-names>E</given-names></name><name><surname>De Luca Cardillo</surname><given-names>C</given-names></name><name><surname>Fioretto</surname><given-names>LM</given-names></name><name><surname>Ribecco</surname><given-names>AS</given-names></name><name><surname>Moretti</surname><given-names>R</given-names></name><name><surname>Scatizzi</surname><given-names>M</given-names></name><name><surname>Zocchi</surname><given-names>G</given-names></name><name><surname>Quattrone</surname><given-names>A</given-names></name></person-group><article-title>Weekly gemcitabine plus epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study</article-title><source>Br J Cancer</source><year>2002</year><volume>87</volume><fpage>497</fpage><lpage>501</lpage><!--PubMed citation query: 'Br J Cancer||87|497||bib6|'--><pub-id pub-id-type="pmid">12189543</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reni</surname><given-names>M</given-names></name><name><surname>Cordio</surname><given-names>S</given-names></name><name><surname>Milandri</surname><given-names>C</given-names></name><name><surname>Passoni</surname><given-names>P</given-names></name><name><surname>Bonetto</surname><given-names>E</given-names></name><name><surname>Oliani</surname><given-names>C</given-names></name><name><surname>Luppi</surname><given-names>G</given-names></name><name><surname>Nicoletti</surname><given-names>R</given-names></name><name><surname>Galli</surname><given-names>L</given-names></name><name><surname>Bordonaro</surname><given-names>R</given-names></name><name><surname>Passardi</surname><given-names>A</given-names></name><name><surname>Zerbi</surname><given-names>A</given-names></name><name><surname>Balzano</surname><given-names>G</given-names></name><name><surname>Aldrighetti</surname><given-names>L</given-names></name><name><surname>Staudacher</surname><given-names>C</given-names></name><name><surname>Villa</surname><given-names>E</given-names></name><name><surname>Di Carlo</surname><given-names>V</given-names></name></person-group><article-title>Gemcitabine <italic>vs</italic> cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial</article-title><source>Lancet Oncol</source><year>2005</year><volume>6</volume><fpage>369</fpage><lpage>376</lpage><!--PubMed citation query: 'Lancet Oncol||6|369||bib7|'--><pub-id pub-id-type="pmid">15925814</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Kornek</surname><given-names>GV</given-names></name><name><surname>Raderer</surname><given-names>M</given-names></name><name><surname>Hejna</surname><given-names>M</given-names></name><name><surname>Valencak</surname><given-names>J</given-names></name><name><surname>Miholic</surname><given-names>J</given-names></name><name><surname>Kovats</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name><name><surname>Funovics</surname><given-names>J</given-names></name><name><surname>Bareck</surname><given-names>E</given-names></name><name><surname>Depisch</surname><given-names>D</given-names></name></person-group><article-title>Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma</article-title><source>Br J Cancer</source><year>1999</year><volume>80</volume><fpage>1797</fpage><lpage>1802</lpage><!--PubMed citation query: 'Br J Cancer||80|1797||bib8|'--><pub-id pub-id-type="pmid">10468299</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Putten</surname><given-names>JW</given-names></name><name><surname>Eppinga</surname><given-names>P</given-names></name><name><surname>Erjavec</surname><given-names>Z</given-names></name><name><surname>de Leede</surname><given-names>G</given-names></name><name><surname>Nabers</surname><given-names>J</given-names></name><name><surname>Smeets</surname><given-names>JB</given-names></name><name><surname>Th Sleijfer</surname><given-names>D</given-names></name><name><surname>Groen</surname><given-names>HJ</given-names></name></person-group><article-title>Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study</article-title><source>Br J Cancer</source><year>2000</year><volume>82</volume><fpage>806</fpage><lpage>811</lpage><!--PubMed citation query: 'Br J Cancer||82|806||bib9|'--><pub-id pub-id-type="pmid">10732750</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Pretreatment characteristics</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Characteristics</bold></th><th align="center" valign="top" charoff="50"><bold><italic>N</italic> (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Number of patients</td><td align="center" valign="top" charoff="50">40</td></tr><tr><td align="left" valign="top" charoff="50">Age, median/range (years)</td><td align="center" valign="top" charoff="50">67.5&#x000b1;8.5 (43&#x02013;75)</td></tr><tr><td align="left" valign="top" charoff="50">Gender (F/M)</td><td align="center" valign="top" charoff="50">16/24 (40/60)</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Karnofsky performance status (KPS)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;60</td><td align="center" valign="top" charoff="50">8 (20)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;70&#x02013;80</td><td align="center" valign="top" charoff="50">25 (62.5)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;90&#x02013;100</td><td align="center" valign="top" charoff="50">7 (17.5)</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Disease stage at presentation</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Stage III</td><td align="center" valign="top" charoff="50">13 (32)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Stage IV</td><td align="center" valign="top" charoff="50">27 (68)</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Histological grade</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;G 1</td><td align="center" valign="top" charoff="50">3 (7.5)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;G 2</td><td align="center" valign="top" charoff="50">26 (65)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;G 3</td><td align="center" valign="top" charoff="50">11 (27.5)</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Prior surgery</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;None</td><td align="center" valign="top" charoff="50">24 (60)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Explorative laparotomy</td><td align="center" valign="top" charoff="50">10 (25)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Palliative bypass</td><td align="center" valign="top" charoff="50">6 (15)</td></tr></tbody></table></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Haematological toxicity (number of patients) in the phase I part of the study</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>WHO toxicity</bold></th><th align="center" valign="top" charoff="50"><bold>Leucocytes</bold></th><th align="center" valign="top" charoff="50"><bold>Granulocytes</bold></th><th align="center" valign="top" charoff="50"><bold>Haemoglobin</bold></th><th align="center" valign="top" charoff="50"><bold>Platelets</bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Level 1</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0&#x02013;1</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Level 2</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0&#x02013;1</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Level 3</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0&#x02013;1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Level 4</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0&#x02013;1</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>Level 1: GEM 800&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x0002b;EPI 35&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>; Level 2: GEM 800&#x02009;mg&#x02009;m&#x02009;<sup>2</sup>&#x0002b;EPI 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>; Level 3: GEM 1000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x0002b;EPI 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>; Level 4: GEM 1000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x0002b;EPI 60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Summary of maximum treatment-associated toxicities (<italic>n</italic>=25) in the phase II part of the study</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="4" align="center" valign="top" charoff="50"><bold>Number of patients/WHO-toxicity grade (&#x00025;)</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Toxicity</bold></th><th align="center" valign="top" charoff="50"><bold>1</bold></th><th align="center" valign="top" charoff="50"><bold>2</bold></th><th align="center" valign="top" charoff="50"><bold>3</bold></th><th align="center" valign="top" charoff="50"><bold>4</bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Haematological and other laboratory-based toxicity</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Leukopenia</td><td align="center" valign="top" charoff="50">3 (12)</td><td align="center" valign="top" charoff="50">4 (16)</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Granulocytopenia</td><td align="center" valign="top" charoff="50">2 (8)</td><td align="center" valign="top" charoff="50">3 (12)</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Thrombocytopenia</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Anaemia</td><td align="center" valign="top" charoff="50">3 (12)</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Bilirubin</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Alkaline phosphatase</td><td align="center" valign="top" charoff="50">3 (12)</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Serum transaminases</td><td align="center" valign="top" charoff="50">3 (12)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Symptomatic toxicity</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Nausea/vomiting</td><td align="center" valign="top" charoff="50">4 (16)</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Stomatitis</td><td align="center" valign="top" charoff="50">2 (8)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Diarrhoea</td><td align="center" valign="top" charoff="50">2 (8)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Constipation</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Infection</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Fever</td><td align="center" valign="top" charoff="50">2 (8)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Alopecia</td><td align="center" valign="top" charoff="50">4 (16)</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Cutaneous</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Phlebitis</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr></tbody></table></table-wrap></floats-wrap></article>


